Elixir Medical Corporation

920 N McCarthy Blvd, Milpitas, California, United States

Clinical Trials

3 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Not Applicable

71.4%

Phase 2

4.8%

Phase 3

4.8%

Phase 4

4.8%

Trial Status Distribution

Active, not recruiting

14.3%

Completed

71.4%

Recruiting

4.8%

Terminated

9.5%

Clinical Trials

Trials sponsored by this organization (21)

DynamX Bioadaptor Global Post-Market Registry: Clinical Trial of the Elixir Medical DynamX Coronary Bioadaptor System

Recruiting

observational

Mar 20245,000 participants

A Clinical Trial to Assess the Elixir Medical LithiX Coronary Hertzian Contact Intravascular Lithotripsy Catheter

Not Applicable

Completed

interventional

Apr 202360 participants

The DESyne BDS Plus RCT: A Randomized Clinical Trial to Assess the Elixir DESyne BDS Plus Drug Eluting Coronary Stent System for the Treatment of de Novo Native Coronary Artery Lesions

Phase 2

Active, not recruiting

interventional

Dec 2021200 participants

Page 1 of 3

Approvals

No approval data available

News

No news articles found

Back to Organizations

Elixir Medical Corporation

Overview

Trial Phase Distribution

Trial Status Distribution

Clinical Trials

Trials sponsored by this organization (21)

DynamX Bioadaptor Global Post-Market Registry: Clinical Trial of the Elixir Medical DynamX Coronary Bioadaptor System

A Clinical Trial to Assess the Elixir Medical LithiX Coronary Hertzian Contact Intravascular Lithotripsy Catheter

The DESyne BDS Plus RCT: A Randomized Clinical Trial to Assess the Elixir DESyne BDS Plus Drug Eluting Coronary Stent System for the Treatment of de Novo Native Coronary Artery Lesions

DYNAMX Bioadaptor ImplanTation for the trEatment of Complex Coronary Lesions

The Elixir Bioadaptor vs. The Onyx Stent in De Novo Native Coronary Arteries

DynamX Bioadaptor Hong Kong Registry

Infinity-Swedeheart Registry Based Randomized Clinical Trial (R-RCT)

DESyne X2 Post Market Follow-up Study

Approvals

News